What is William Blair’s Forecast for Alector Q1 Earnings?

Alector, Inc. (NASDAQ:ALEC) – Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Alector in a research report issued to clients and investors on Thursday, February 27th. William Blair analyst M. Minter expects that the company will earn ($0.54) per share for the quarter. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. William Blair also issued estimates for Alector’s Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.54) EPS and Q4 2026 earnings at ($0.52) EPS.

Alector (NASDAQ:ALEC) last announced its earnings results on Wednesday, February 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.59. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. The firm had revenue of $54.24 million during the quarter, compared to analyst estimates of $20.41 million.

Several other brokerages have also issued reports on ALEC. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Alector in a research report on Thursday. Morgan Stanley lowered Alector from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $10.00 to $3.00 in a research report on Tuesday, November 26th. Bank of America lowered Alector from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $9.00 to $1.00 in a research report on Wednesday, December 4th. BTIG Research reduced their price objective on Alector from $16.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, November 26th. Finally, Mizuho lowered Alector from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $9.00 to $2.50 in a research report on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $3.75.

Alector Stock Performance

Shares of NASDAQ:ALEC opened at $1.66 on Friday. Alector has a 52-week low of $1.55 and a 52-week high of $7.58. The firm has a market capitalization of $162.57 million, a P/E ratio of -0.98 and a beta of 0.61. The stock has a 50 day moving average price of $1.78 and a 200-day moving average price of $3.53.

Institutional Trading of Alector

Several institutional investors have recently added to or reduced their stakes in the business. FMR LLC boosted its stake in Alector by 1.0% during the 3rd quarter. FMR LLC now owns 14,595,014 shares of the company’s stock valued at $68,013,000 after purchasing an additional 137,794 shares during the last quarter. RA Capital Management L.P. purchased a new position in shares of Alector in the 4th quarter worth $18,324,000. JPMorgan Chase & Co. boosted its stake in shares of Alector by 64.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company’s stock worth $12,716,000 after buying an additional 1,072,298 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Alector by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,914,250 shares of the company’s stock worth $3,619,000 after buying an additional 10,308 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C boosted its stake in shares of Alector by 1.1% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,066,962 shares of the company’s stock worth $2,017,000 after buying an additional 11,770 shares during the last quarter. 85.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Alector

In other Alector news, insider Sara Kenkare-Mitra sold 26,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $2.52, for a total transaction of $66,780.00. Following the sale, the insider now directly owns 565,215 shares in the company, valued at approximately $1,424,341.80. This trade represents a 4.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Marc Grasso sold 16,489 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $2.52, for a total value of $41,552.28. Following the sale, the chief financial officer now owns 330,651 shares in the company, valued at approximately $833,240.52. This represents a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 95,161 shares of company stock valued at $239,806 in the last 90 days. Corporate insiders own 9.10% of the company’s stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.